Bolt Biotherapeutics, Inc. BOLT 深 滬
等待開盤 09-08 09:30:00 美东时间
3.90
+0.005
+0.13%
華盛通- 最 高3.9999
- 今 開3.90
- 成交量 8506股
- 最 低 3.845
- 昨 收 3.895
- 總市值 751.27万
- 52周最高 7.1999
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 3.13
- 委 比 -87.01%
- 總股本 192.63万
- 歷史最高 861.40
- 量 比 0.54
- 振 幅 3.98%
- 歷史最低 3.13
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Wes Burwell has joined Nurix Therapeutics as Chief Human Resources Officer, bringing over 20 years of leadership experience in scaling organizations through clinical development and commercialization. He will lead Nurix's human resources team as the company advances its late-stage clinical pipeline and prepares for commercialization. Burwell previously served as vice president of human resources at Bolt Biotherapeutics and held senior HR roles at...
08-20 11:00
Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-12 23:17
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share from the same period last year. The company reported quarterly sales of $5.000 t...
08-12 04:20
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
05-28 18:39
Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses of $(5.80) per share
05-13 05:19
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
03-13 18:12
Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of $(7.60) per share
03-13 04:14
